Merck: Studies boost Gardasil for new uses

The Miami Herald

National Business

AP Business Writer

The Gardasil vaccine protected most ( how many is most??) young women from cervical cancer and homosexual men from anal cancer, according to new studies released Wednesday by its maker, Merck & Co.

The vaccine is designed to block four of the most common strains of the sexually transmitted human papilloma virus, or HPV. Two of those HPV strains cause the majority of cases of cervical cancer and anal cancer, and the other two can cause genital warts.

Gardasil, Merck’s top-selling vaccine, already is approved for prevention of cervical cancer and genital warts in girls and women aged 9 to 26. It’s also approved for preventing genital warts in boys and men aged 9 to 26.

Data from the new studies will be used to seek approval from the Food and Drug Administration to also market Gardasil for preventing cervical cancer and genital warts in women up to age 45 and for preventing anal cancer in males.

Merck, which is based in Whitehouse Station, N.J., funded both studies.


The time has come for independent studies on this vaccine.  Enough is enough Merck.  You have already been accused a falsifying information – and how many is MOST girls protected by Gardasil.  If I said that MOST girls were injured by Gardasil you would throw out the argument.  And the damn vaccine has only been on the market for 3 years so how can you say ANYONE has been protected from cervical cancer. The NVIC lists 274 cases of abnormal paps within 2 years post vaccination. Explain that one.


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.